Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 8, 2010

View Archived Issues

Preclinical and early clinical data reported on BC-3781

Extended proof-of-concept and drug interaction studies complete for IDX-899

Eisai details in vitro and in vivo activity of new antifungal E-1210

Researchers claim new glucokinase activators

SEPS Pharma presents new fluconazole prodrugs for fungal infections

Stemsynergy Therapeutics claims new Wnt signaling inhibitors

Deakin University presents new antibacterial agents

CH-14.18 shows promise in phase III trial in neuroblastoma

MV-062926 is active in mouse model of COPD

FDA accepts Accera's IND application for phase II/III AC-1204 trial in AD

NCI and Lixte Biotechnology collaborate on anticancer agent LB-100

ISTO Technologies' phase I trial of NuQu in discogenic back pain fully enrolled

NeuroSearch patents new voltage-gated K(V)7 potassium channel modulators

Roche buys rights to hepatitis C therapy danoprevir from InterMune

Sirius Genomics receives NRC-IRAP funding for discovery of genomic biomarkers

NIH funds Profectus BioSciences to develop HIV vaccine

Bepotastine besilate nasal spray is efficacious in allergic rhinitis

Sucampo submits marketing application for Amitiza in Japan

Xeomin launched in U.S. for cervical dystonia and blepharospasm

Pfizer acquires FoldRx Pharmaceuticals

FDA agrees to SPA for phase III Estybon trial in myelodysplastic syndromes

Recruitment complete in phase II tideglusib trial in progressive supranuclear palsy

DynPort Vaccine begins phase IIb trial of recombinant plague vaccine

ChemGenex completes pre-NDA meeting with FDA for Omapro

Neoprobe completes Lymphoseek pre-NDA meeting

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...